Logo image of ATRA

ATARA BIOTHERAPEUTICS INC (ATRA) Stock Fundamental Analysis

NASDAQ:ATRA - US0465132068 - Common Stock

12.46 USD
+0.11 (+0.89%)
Last: 8/28/2025, 2:19:31 PM
Fundamental Rating

3

ATRA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. ATRA has a medium profitability rating, but doesn't score so well on its financial health evaluation. While showing a medium growth rate, ATRA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ATRA had negative earnings in the past year.
ATRA had a negative operating cash flow in the past year.
ATRA had negative earnings in each of the past 5 years.
In the past 5 years ATRA always reported negative operating cash flow.
ATRA Yearly Net Income VS EBIT VS OCF VS FCFATRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

ATRA has a Return On Assets of 15.70%. This is amongst the best in the industry. ATRA outperforms 95.80% of its industry peers.
The Return On Invested Capital of ATRA (83.02%) is better than 100.00% of its industry peers.
Industry RankSector Rank
ROA 15.7%
ROE N/A
ROIC 83.02%
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRA Yearly ROA, ROE, ROICATRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

The Profit Margin of ATRA (3.07%) is better than 90.86% of its industry peers.
ATRA has a Operating Margin of 12.44%. This is amongst the best in the industry. ATRA outperforms 93.42% of its industry peers.
With an excellent Gross Margin value of 81.24%, ATRA belongs to the best of the industry, outperforming 85.01% of the companies in the same industry.
Industry RankSector Rank
OM 12.44%
PM (TTM) 3.07%
GM 81.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRA Yearly Profit, Operating, Gross MarginsATRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ATRA is creating value.
The number of shares outstanding for ATRA has been increased compared to 1 year ago.
ATRA has less shares outstanding than it did 5 years ago.
The debt/assets ratio for ATRA is higher compared to a year ago.
ATRA Yearly Shares OutstandingATRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATRA Yearly Total Debt VS Total AssetsATRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -68.15, we must say that ATRA is in the distress zone and has some risk of bankruptcy.
ATRA has a Altman-Z score of -68.15. This is amonst the worse of the industry: ATRA underperforms 93.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -68.15
ROIC/WACC9.81
WACC8.46%
ATRA Yearly LT Debt VS Equity VS FCFATRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 1.70 indicates that ATRA should not have too much problems paying its short term obligations.
The Current ratio of ATRA (1.70) is worse than 78.61% of its industry peers.
A Quick Ratio of 1.70 indicates that ATRA should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.70, ATRA is doing worse than 77.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.7
ATRA Yearly Current Assets VS Current LiabilitesATRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

ATRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.91%, which is quite impressive.
The Revenue has grown by 202.40% in the past year. This is a very strong growth!
ATRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 85.07% yearly.
EPS 1Y (TTM)98.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.13%
Revenue 1Y (TTM)202.4%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-38.63%

3.2 Future

Based on estimates for the next years, ATRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.96% on average per year.
The Revenue is expected to grow by 9.85% on average over the next years. This is quite good.
EPS Next Y91.7%
EPS Next 2Y38.41%
EPS Next 3Y20.87%
EPS Next 5Y19.96%
Revenue Next Year3.06%
Revenue Next 2Y-37.22%
Revenue Next 3Y-41.47%
Revenue Next 5Y9.85%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ATRA Yearly Revenue VS EstimatesATRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ATRA Yearly EPS VS EstimatesATRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATRA. In the last year negative earnings were reported.
Also next year ATRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATRA Price Earnings VS Forward Price EarningsATRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ATRA is valued cheaper than 98.54% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.56
ATRA Per share dataATRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

A more expensive valuation may be justified as ATRA's earnings are expected to grow with 20.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.41%
EPS Next 3Y20.87%

More info and screens

0

5. Dividend

5.1 Amount

ATRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATARA BIOTHERAPEUTICS INC

NASDAQ:ATRA (8/28/2025, 2:19:31 PM)

12.46

+0.11 (+0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-10 2025-11-10
Inst Owners51.11%
Inst Owner Change-13.54%
Ins Owners3.06%
Ins Owner Change1.51%
Market Cap87.47M
Analysts80
Price Target16.83 (35.07%)
Short Float %3.82%
Short Ratio3.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)206.91%
Min EPS beat(2)140.49%
Max EPS beat(2)273.33%
EPS beat(4)3
Avg EPS beat(4)108.14%
Min EPS beat(4)-48.64%
Max EPS beat(4)273.33%
EPS beat(8)5
Avg EPS beat(8)42.3%
EPS beat(12)6
Avg EPS beat(12)18.14%
EPS beat(16)9
Avg EPS beat(16)16.65%
Revenue beat(2)2
Avg Revenue beat(2)866.25%
Min Revenue beat(2)134.43%
Max Revenue beat(2)1598.08%
Revenue beat(4)4
Avg Revenue beat(4)453.06%
Min Revenue beat(4)12.04%
Max Revenue beat(4)1598.08%
Revenue beat(8)5
Avg Revenue beat(8)208.9%
Revenue beat(12)5
Avg Revenue beat(12)115.29%
Revenue beat(16)8
Avg Revenue beat(16)126.52%
PT rev (1m)7.61%
PT rev (3m)7.61%
EPS NQ rev (1m)-13.96%
EPS NQ rev (3m)39.53%
EPS NY rev (1m)32.34%
EPS NY rev (3m)78.97%
Revenue NQ rev (1m)-75.14%
Revenue NQ rev (3m)-94.13%
Revenue NY rev (1m)77.06%
Revenue NY rev (3m)245.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.46
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 3.56
EPS(TTM)-0.43
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-9.12
FCFYN/A
OCF(TTM)-9.1
OCFYN/A
SpS26.88
BVpS-4.99
TBVpS-4.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 15.7%
ROE N/A
ROCE 105.09%
ROIC 83.02%
ROICexc 115908%
ROICexgc 115908%
OM 12.44%
PM (TTM) 3.07%
GM 81.24%
FCFM N/A
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover5.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 1.44
Cap/Depr 2.06%
Cap/Sales 0.05%
Interest Coverage 52.87
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.7
Quick Ratio 1.7
Altman-Z -68.15
F-Score5
WACC8.46%
ROIC/WACC9.81
Cap/Depr(3y)34.79%
Cap/Depr(5y)54.33%
Cap/Sales(3y)7.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.13%
EPS Next Y91.7%
EPS Next 2Y38.41%
EPS Next 3Y20.87%
EPS Next 5Y19.96%
Revenue 1Y (TTM)202.4%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-38.63%
Revenue Next Year3.06%
Revenue Next 2Y-37.22%
Revenue Next 3Y-41.47%
Revenue Next 5Y9.85%
EBIT growth 1Y114.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.24%
EBIT Next 3Y15.72%
EBIT Next 5Y-3.99%
FCF growth 1Y70.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.02%
OCF growth 3YN/A
OCF growth 5YN/A